ABeterno has devised a new and unique approach to cell separation and live cell imaging, using intracellular proteins to isolate viable whole cells.
This will open up the capability to research a much broader range of therapeutically important proteins than has to date been possible. In the case of live cell imaging, it will also eradicate a highly complex and time consuming process.
Antitope is pioneering a new generation of immunogenicity testing and protein engineering technologies. Their mission is to apply these technologies to create improved non-immunogenic biologics.
Axol Bioscience provides human induced pluripotent stem (iPS) cell-derived neural stem cells and neurons for life science research.
Bicycle Therapeutics is a newly formed biotechnology company developing a novel technology for the creation of a new generation of biotherapeutics. Bicycle technology utilises biological selection techniques to select and optimise peptides with high binding affinities which are constrained by an organo-chemical scaffold. This enables the creation of novel molecules which combine the desirable features of small molecules and biopharmaceuticals. The technology is based on the work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Prof. Christian Heinis and Prof. Sir Gregory Winter.
Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia and Cambridge, UK. Biosceptre is developing and commercializing antibody technologies to address a wide range of applications in the diagnosis and treatment of cancer.
P2X7 is a major cellular receptor responsible for normal programmed cell death. Biosceptre’s technology is based on the fundamental discovery of a subtly changed form of P2X7 that is found on all solid cancer cells, but never on normal cells and acts as a key driver for malignancy. Biosceptre has developed and patented a range of polyclonal, monoclonal and domain antibodies that bind to the non-functional form of P2X7 (nf-P2X7) on cancer cells, but not to normal P2X7.
Biosceptre is also working with collaborators on developing other technologies such as the clinical use of dendritic cell vaccinations against our novel target.
Cambimune is a biotechnology company focused on the research, development and commercialisation of innovative biologicals and other biomedical technologies
Cambivac® Ltd researches, develops and out-licenses innovative vaccine technologies. We benefit from a close relationship with the University of Cambridge which facilitates our aims of bringing together world class expertise in the fields of traditional virology, modern genomics and molecular vaccine approaches. We adopt a multi-disciplinary approach towards providing novel solutions to current and emerging disease challenges; particularly well suited to zoonotic disease challenges which are of ever increasing importance - given the fact that 75% of emerging human diseases are zoonotic.
Cambridge Epigenetix (CEGX) is a biosciences company that aims to be the world leading provider of high quality, easy to use epigenetic tools. Their flagship product is TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethylcytosine (5hmC) and methylcytosine (5mC).
Cambridge Protein Arrays Ltd is an early stage biotech company, established by Dr Mike Taussig in 2010 in order to carry out Research and Development in the area of protein arrays and their applications in proteomics. The company is using the expertise developed within the Protein Technology Group at Babraham Bioscience Technologies (BBT) in Cambridge, and aims to commercialise the systems they have developed for printing protein arrays from DNA arrays.
Profile to follow.
Profile to follow.
Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com.
CCCR Cambridge Ltd. was established in Autumn 2012 and it is a spin-off company to the Competence Centre for Cancer Research (www.vtak.ee/en/). The company has almost 10 years of experience in R&D with the focus on cancer research. Our mission is to improve the quality of cancer therapy by developing and implementing new diagnostic platforms and offering the pharmaceutical industry new drug candidates. We have 10 applied projects and 3 basic research projects in our project portfolio. We offer cooperation possibilites in various EU projects.
Cell Guidance Systems develops and manufactures reagents for life science research and biomanufacturing. The Company focuses on stem cells and has developed two key technology platforms. The first, Pluripro® defined media and substrate reagents, allow for confluent culture of pluripotent cells. Pluripro® technology simplifies and significantly reduces the cost of human ES and iPS cell culture. The Company’s second technology platform, STAR growth factors, uses a proprietary modification process that addresses cost and performance issues for growth factors. The modified growth factors develop orders-of-magnitude improvement in biological activity. Our initial focus is on the commercial launch of growth factors that will address cost and performance issues currently hampering the development of stem cell therapeutics.
Convergence Pharmaceuticals is focused on the development of novel analgesics with commercially attractive efficacy, responder-rate and side effect profiles. The Company is an independent biotechnology company which was formed in October 2010 following the acquisition of clinical assets from GlaxoSmithKline. Convergence Pharmaceuticals’ pipeline of differentiated clinical-stage compounds targets the points of convergence in chronic pain signaling through modulation of specific ion-channels. The Company is well funded and raised $35.4 million (£22.4 million) in Series A financing from a syndicate of leading European and US VCs. Convergence Pharmaceuticals’ management team is led by Clive Dix, Chief Executive Officer (ex PowderMed, PowderJect, Glaxo Wellcome), Simon Tate, Chief Scientific Officer (ex GSK) and Brenda Reynolds, Chief Operating Officer (ex PowderMed, PowderJect, Pfizer). The team collectively has extensive experience in leading successful biotech ventures and in drug development.
Crescendo Biologics is building a pipeline of novel medicines based on its highly innovative VH antibody fragment platform through both in-house development and strategic partnerships. Crescendo’s proprietary VH technology produces human heavy chain-only antibodies in the transgenic Crescendo Mouse providing a unique source of fully human VH fragments that have matured in vivo to have high affinity, stability and solubility. VH fragments are the smallest antibody fragments that retain binding affinity and specificity offering the potential to generate novel products with improved drug-like properties and able to address unmet medical needs.
Crescendo’s technologies originated from discoveries by scientists at the Babraham Institute, Cambridge (UK). The company has raised funding totalling £7.7 million from an investment consortium led by Sofinnova Partners with Avlar BioVentures, Babraham Bioscience Technologies, and the Rainbow Seed Fund.
Providing industrial quantities of human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.
DiagNodus is a biomedical company, the principal direction of which is the development of a new non-invasive approach to colorectal cancer screening based upon introduction of an innovative rapid ‘point of care’ test. The company works on several versions of the product, some of which may also be applicable for non-invasive testing for a wider range of gastrointestinal conditions aiming improved disease detection, differential diagnosis and monitoring.
Discerna is an emerging company developing innovative protein technologies for application to the discovery and analysis of biopharmaceuticals. Recognising the commercial potential of recombinant protein-based products, particularly antibodies, Discerna has created a platform of technologies that both improve upon and complement established methods of developing biopharmaceuticals. Proprietary technologies include ribosome display and in-situ protein arrays.
Eagle Genomics supplies quality outsourced bioinformatics solutions. We combine cloud computing and Next Generation Sequencing (NGS) expertise with a track record in building scalable, efficient genomics analysis workflows using both commercial and open source software. Our services have added value to R&D processes and reduced time to market at many global life sciences companies including big pharma, crop science, personal hygiene and animal health.
F-star develops bispecific antibody products to improve the treatment of serious diseases. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of bispecific antibody products.
ImmunoBiology Limited (ImmBio) is a biotechnology company developing the next generation of vaccines for the prevention and treatment of infectious diseases by applying its proprietary HspC™ vaccine technology platform to development of breakthrough products.
Innovations creates, builds and invests in pioneering university technologies addressing global problems in healthcare, energy, engineering and the environment. It combines deep understanding of science and technology with commercial acumen and strong investment expertise.
Innovations supports scientist-entrepreneurs in the commercialisation of their ideas by:
-leading the formation of new companies and providing facilities in the early stages
-providing significant investment and encouraging co-investment to accelerate the transition from R&D to products
- providing operational expertise
- helping to recruit high-calibre industry figures and experienced entrepreneurs as executive management and Board members
Innovations invests in companies based on technologies from or associated with four universities: Imperial College London; and Cambridge University, Oxford University, and UCL supported by its collaborations with Cambridge Enterprise, OSEM and UCL Business. These are the UK’s leading research intensive universities, measured by research income.
Innova Biosciences, based in Cambridge, UK, specialises in providing highly effective solutions for all your bioconjugation challenges. Problems such as poor yield, batch to batch variation and low sensitivity are all overcome by using our core labelling technologies of Lightning-Link®, InnovaCoat® and Thunder-Link®.
These technologies simplify labelling of antibodies and other proteins to enzymes, fluorescent dyes, gold nanoparticles and oligonucleotides, and are suitable for both small scale R&D and large scale manufacturing.
In addition to our extensive range of conjugation kits we are pleased to offer bespoke solutions for custom manufacturing of your conjugate needs, directly accessing the expertise of our specialists.
Kymab is using embryonic stem cell technology to develop its Kymouse™ platform, which encompasses the entire diversity of the B lymphocyte component of the human immune system. This will allow the discovery of highly selective, potent and well-tolerated monoclonal antibody-based biopharmaceuticals. These new drugs will include best-in-class antibodies directed against clinically precedented drug targets and first-in-class drugs against novel targets.
Rainbow was launched in May 2002 and comprises a partnership of publicly funded research laboratories with funding of £10 million provided by the Department of Business, Innovation and Skills. The Rainbow Seed Fund provides investment to support the early stages of commercialisation of technology and services from its partners, which include the Science and Technology Facilities Council, the Defence Science and Technology Laboratory, the Natural Environment Research Council and the Biotechnology and Biological Sciences Research Council. This wide base of research Rainbow makes individual investments of between £10,000 and £500,000 in promising spin-out companies. Find out more about the fund by talking to Andrew Muir or Mark White.
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.
MISSION Therapeutics holds and will maintain world-leadership in DNA repair and associated molecular pathways. The company will use its knowledge and proven expertise in targeting these pathways for small-molecule drug discovery to develop new therapeutic agents with wide market potential. These drugs will mainly target "Achilles heels" of diseased tissues by exploiting the concept of synthetic-lethality.
Mission Therapeutics was founded by Professor Steve Jackson, a world expert on the DNA damage response. Steve is Senior Group Leader and Head of Cancer Research UK Laboratories in the Gurdon Institute, Cambridge University and is the University's Frederick James Quick Professor of Biology. For information on his research, see http://www.gurdon.cam.ac.uk/~jacksonlab/
Nemesis Bioscience has designed, and is developing, pioneering technologies that will resurrect anti-microbial therapies made ineffective by increasing microbial resistance.
These unique therapeutics will impact one of the world's most significant clinical problems by not only treating antibiotic resistant infections, but also by preventing them in susceptible patients.
NorayBio is a bioinformatics company that supports the life sciences sector: biotechnology, biomedicine and biopharmaceuticals, developing new software solutions. We specialise in software for Biobanks, Animal Research and biotechnology companies and laboratories.
Company headquarters are based in Bilbao, north of Spain, and currently the company has three sales offices in Europe, in Cambridge, Lyon and Turin, with the aim to support foreign customers and open new markets. NorayBio does also have a strategic alliance with the British Aston Pharma as commercial agent in the UK. NorayBio is Microsoft Certified Partner and part of Oracle Partner Network, as well as ISO 9001:2008 accredited.
Phico Therapeutics is an early stage biotechnology company developing a novel platform technology to produce therapeutic anti-bacterials active against all species of bacteria. Initial products in development are targeted at antibiotic resistant bacteria, including MRSA.
To develop technology invented by Nobel Laureate, Sydney Brenner, for obtaining sequence information from thousands of genomes simultaneously. Applications include the discovery of genetic variations affecting common diseases and the development of safer more effective drugs. Current technologies can only analyse one genome at a time. The Wellcome Trust has granted £1.1m to begin development of the technology, pending receipt of additional Venture Capital investments. The IP and related patent applications underlying the technology were licensed from Compass Genetics LLC, a partnership formed by Drs Sydney Brenner, Sam Eletr and Philip Goelet.
Proximagen Limited is focused on the development and commercialisation of novel therapeutics for diseases of the CNS, neuroinflammation/inflammation and oncology. The Company is developin a broad pipeline of drug candidate programmes and has plans for substantial future growth through acquiring and developing innovative drug candidate programmes. The Company's strong balance sheet makes Proximagen one of the best capitalised biotechnology companies in the UK.
Rapid Biosensor Systems Ltd is an innovative technology and business development Company with experience in development and commercial exploitation of IPR for rapid screening infectious diseases. Their skills are in business management, technology development, photonics, biochemistry, and medical consultancy. RBS can assist with the concepts right through to production. Their first product is a "Breathalyser" style device for screening Tuberculosis (TB) at the Point-of-Test. The product is designed to be small, rugged, simple to use and low cost. Furthermore, the device minimizes both the need for training and the risk of infection of the operator.
Recombinant Antibody Technology Ltd. is specializing in the generation of large recombinant DNA constructs using YAC and BAC technologies. Currently, the company is working with Open Monoclonal Technology, Inc., a US based biotechnology company, on the generation of recombinant immunoglobulin loci for the generation of genetically engineered rats expressing antibodies with fully human idiotypes.
RxCelerate is an out-sourced drug development company, delivering complete preclinical drug development programmes and project management for virtual and semi-virtual companies. Our services include routine animal models of human diseases, toxicology and ADME studies. We offer innovative experimental designs (combining efficacy, toxicology and pharmacokinetic end-points in one study or using multivariate statistical frameworks to examine multiple end-points in a single study design) coupled with more than 20 years experience of drug discovery and development. RxCelerate delivers cutting-edge development capability at the same time as cutting costs and timelines to client companies large and small.
Sphere Fluidics has developed a new technology platform for single cell analysis and characterisation which enables the discovery and development of new biopharmaceuticals and novel ways to study single cell diseases, e.g. cancer.
The Company has patented novel biochip systems that automatically process tens of millions of miniaturised tests in picodroplets. Sphere Fluidics can find that rare “one in a million” molecule or cell that could be an industry blockbuster. Compared to conventional approaches, our technology is very fast and miniaturised - offering tremendous cost-savings.
SC Proven® STEM CELL RESEARCH AND DRUG DISCOVERY TOOLS Stem Cell Sciences (UK) Ltd., a wholly owned subsidiary of StemCells Inc. (USA), is a global biotechnology company focused on the development, manufacture and distribution of SC Proven® stem cells and cell culture reagents, and Automated Cell Production capability for biopharmaceutical research and clinical applications. The Parent Company StemCells Inc.' core business objective is to develop its proprietary and lead 'first in man' therapeutic product candidate, HuCNS-SC® (purified human neural stem cells), currently in development as a potential treatment for a broad range of central nervous system disorders and injuries, including myelination and Alzheimer's disorders, dry age-related macular degeneration (AMD) and spinal cord injury.
STX Pharma is developing novel anti-inflammatory drugs that induce resolution of chronic inflammation in conditions such as allergic asthma and rheumatoid arthritis. Our drugs are based on a technology platform developed at Cambridge University in 2003, following the discovery of somatotaxins - natural peptides with a C-terminal lactam group, a novel post-translational modification, that confers binding to the type 2 somatostatin receptor. These peptides are important for the normal resolution of inflammation, and low levels of somatotaxins are associated with inflammatory diseases. STX Pharma has a number of synthetic somatotaxins under development as novel therapeutics.
Synome offers a versatile battery of in vitro electrophysiological tests. Our aim is to accelerate the discovery of novel drugs for treatment of mental disorders by utilising multiplexing capabilities of multi-electrode arrays technology. Synome’s scientists have experience from large-scale electrophysiological screening of more than 50 transgenic mouse lines. Synome is a member of 4 academic EU Framework Programme 7 projects (EUROSPIN, SynSYS, GENCODYS, PharMEA) aimed at the elucidation of roles of synaptic proteins in brain disorders. We also aim to establish an in-house pipeline of drug leads in the CNS area.
Established in 2007, SYNthesis med chem (Synmedchem) is a global organisation providing synthetic and medicinal chemistry services. The company operates a unique, “best of both worlds” business model combining Western medicinal chemistry expertise with cost effective and scalable synthetic chemistry based in China. Synmedchem's UK based medicinal chemists provide the design, innovation, creativity and problem solving expertise required to complement the skills & capabilities of Synmedchem's synthetic chemists. The company’s medicinal chemists are all experienced and highly skilled scientists with a track record of delivering clinical candidates, a passion for discovering new medicines and a comprehensive insight gained from managing more than 100 projects covering all phases of the pharma pipeline. They also act as project managers for all custom synthesis and medicinal chemistry projects as locally based expertise enables seamless Synmedchem/client communication.
Talisman Therapeutics Ltd is a human stem cell drug discovery company. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and relevant compound identification, which significantly accelerate drug discovery. Talisman’s primary goal is the exploitation of these systems to identify novel pharmacological treatments for Alzheimer’s disease initiation and progression through our in-house drug discovery programme. We also work with other organisations, on a collaborative basis, to maximise the impact of our own and their research and development activities. We collaborate with other organisations to assist with their drug discovery efforts. Partners include large pharmaceutical companies, small biotech businesses and universities.
Total Scientific is a contract research organisation with experience in all aspects of biomarker research, from identification of the biomarker using 'omics technology through independent assay design, development, optimisation and validation to multi-site clinical studies designed to validate or test biomarkers. However, in addition to these biomarker-related activities we can provide a large range of scientific expertise and consultancy relating to data management and biostatistics, multiplex technology and immunology.
Twist Dx Ltd is a company developing proprietary technology in the area of DNA amplifications and sequencing. Their novel approach to acquiring sequences from individual DNA strands, Direct Nucleic Acid Sequencing (DNAS), will permit the analysis of entire genomes in only days or hours. Twist Dx Ltd is also exploring novel and improved ways of amplifying target DNA sequences for applications in the life sciences.
UroSens is developing a simple and highly sensitive test for bladder cancer based on detection of the marker protein Mcm5 in patients' urine. The test will be used in differential diagnosis in patients with haematuria or other symptoms and for surveillance and disease monitoring. There are over 140,000 new cases of bladder cancer a year in Europe and the US and over a million people live with the disease. The condition has a high recurrence rate, therefore frequent post-treatment testing is required. UroSens' test addresses the key disadvantages of invasiveness and high cost associated with bladder endoscopy, the current gold standard diagnostic method.
XO1 is a virtual company, developing ichorcumab - a novel anticoagulant that does not cause bleeding. Inappropriate blood clotting (thrombosis) is a major cause of morbidity and mortality in, for example, strokes and heart attacks. Conventional anticoagulants reduce this harmful blood clotting, but do so at the cost of increasing bleeding risk. Ichorcumab is a synthetic version of a natural-occurring human anti-thrombin antibody that confers powerful anti-thrombotic effects but without preventing the normal blood clotting that stops bleeding. XO1, Business Weekly Start-Up of the Year 2014, is progressing ichorcumab into clinical trials as rapidly as possible through engagement of carefully selected service providers with specialist expertise in all the key areas of drug development.
Babraham Bioscience Technologies Ltd - Cambridge - United Kingdom